Abbott (NYSE:ABT) today announced the company has capacity and supply to effectively support the growing demand for mechanical circulatory support (MCS) devices for the effective treatment of advanced heart failure following Medtronic’s decision to stop the global distribution and sale of the Medtronic HeartWare™ ventricular assist device (HVAD). Abbott is also supporting training and education programs for additional physicians who will now be offering Abbott’s HeartMate 3™ heart pumps to their patients.
FDA Clears Curis’ Lymphoma Study, Keeping Leukemia Trial Still Stalled
The FDA has lifted the partial clinical hold on Curis Inc’s (NASDAQ:CRIS) TakeAim Lymphoma Phase 1/2 study of emavusertib after reviewing the…
